Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Background/Aims Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods Using data f...

Full description

Bibliographic Details

Published in:	Clinical and Molecular Hepatology
Main Authors:	Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-10-01
Subjects:	hepatocellular carcinoma immunotherapy atezolizumab bevacizumab transcriptome
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0333.pdf